Physician profile
Cara Mcleod
NPI 1205246246
$5,560.00
in general payments reported to CMS, 2019-2025
22 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $99.39 · 2021: $95.72 · 2022: $1,037 · 2023: $1,239 · 2024: $909 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,485 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,484.87 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,854.41 | 2019-2025 | |
| Amgen INC. | $774.35 | 2021-2025 | Tavneos, Enbrel, Otezla |
| Novartis Pharmaceuticals Corporation | $701.90 | 2019-2025 | |
| Janssen Biotech, INC. | $439.75 | 2021-2025 | Tremfya |
| Glaxosmithkline, LLC. | $326.75 | 2022-2025 | Benlysta, Nucala |
| Ucb, INC. | $241.99 | 2022-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $238.56 | 2022-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $169.29 | 2022-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.24 | 2021-2025 | Ofev, Cyltezo |
| Aurinia Pharma U.S., INC. | $106.44 | 2022-2024 | Lupkynis |
| Pfizer INC. | $101.84 | 2022-2024 | |
| Octapharma USA, INC. | $75.52 | 2023-2025 | Octagam Immune Globulin (Human), Panzyga |
| Invivyd INC | $65.50 | 2025 | Pemgarda |
| Horizon Therapeutics Plc | $51.58 | 2023 | Krystexxa |
| Genzyme Corporation | $51.43 | 2023-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $49.66 | 2024-2025 | Orencia |
| Lilly USA, LLC | $42.06 | 2022-2025 | Zepbound, Taltz |
| Alexion Pharmaceuticals, INC. | $33.76 | 2024-2025 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $30.24 | 2023-2024 | Opsumit, Uptravi |
| Genentech USA, INC. | $22.66 | 2022 | |
| Radius Health, INC. | $21.51 | 2025 | Tymlos |
| Sandoz INC. | $19.56 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Mcleod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.